FDA lifts hold on Pluristem’s stem cell trial after tweaking protocol – FierceBiotech
|
FDA lifts hold on Pluristem’s stem cell trial after tweaking protocol
FierceBiotech Israel’s Pluristem Therapeutics ($PSTI) says the FDA has given the company a green light to push ahead on a mid-stage study of one of its stem cell therapies after the agency had finished its review of one patient’s severe allergic reaction and tweaked … FDA lifts hold on Pluristem Therapeutics studyBusinessweek FDA lets Pluristem continue Phase 2 trialGlobes |
